Catalent Stock Today
| CTLT Stock | USD 56.08 0.22 0.39% |
Performance10 of 100
| Odds Of DistressLess than 29
|
Catalent is selling for under 56.08 as of the 16th of April 2024; that is -0.39 percent down since the beginning of the trading day. The stock's last reported lowest price was 56.05. Catalent has about a 29 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat ok performance during the last 90 days. Equity ratings for Catalent are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of April 2022 and ending today, the 16th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of July 2014 | Category Healthcare | Classification Health Care |
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey. The company has 180.74 M outstanding shares of which 7.51 M shares are currently shorted by private and institutional investors with about 3.39 trading days to cover. More on Catalent
Moving against Catalent Stock
| 0.74 | NVS | Novartis AG ADR Earnings Call This Week | PairCorr |
| 0.71 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
| 0.68 | BNR | Burning Rock BiotechLtd Financial Report 4th of June 2024 | PairCorr |
| 0.58 | IVA | Inventiva Sa | PairCorr |
| 0.53 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 10th of June 2024
Catalent Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Catalent's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Catalent or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | John Chiminski | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Obamacare Repeal (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, SP 500 Index, ARCA Pharmaceutical, Obamacare Repeal, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Catalent report their recommendations after researching Catalent's financial statements, talking to executives and customers, or listening in on Catalent's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Catalent. The Catalent consensus assessment is calculated by taking the average forecast from all of the analysts covering Catalent. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Catalent's liquidity, profitability, solvency, and operating efficiency, Catalent is not in a good financial situation at this time. It has a very high probability of going through financial hardship in May. Financial strength of Catalent is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Catalent's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Catalent's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Catalent's financial leverage. It provides some insight into what part of Catalent's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Catalent (CTLT) is traded on New York Stock Exchange in USA. It is located in 14 Schoolhouse Road, Somerset, NJ, United States, 08873 and employs 18,000 people. Catalent is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 10.18 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Catalent's market, we take the total number of its shares issued and multiply it by Catalent's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Catalent conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 180.74 M outstanding shares of which 7.51 M shares are currently shorted by private and institutional investors with about 3.39 trading days to cover.
Catalent currently holds about 345 M in cash with 261 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.92.
Check Catalent Probability Of Bankruptcy
Ownership AllocationCatalent retains a total of 180.74 Million outstanding shares. The majority of Catalent outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Catalent to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Catalent. Please pay attention to any change in the institutional holdings of Catalent as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Catalent Ownership Details
Catalent Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Catalent jumping above the current price in 90 days from now is about 39.44%. The Catalent probability density function shows the probability of Catalent stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Catalent has a beta of 0.2693 suggesting as returns on the market go up, Catalent average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Catalent will be expected to be much smaller as well. Additionally, catalent has an alpha of 0.1831, implying that it can generate a 0.18 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Catalent to move above the current price in 90 days from now is about 39.44 (This Catalent probability density function shows the probability of Catalent Stock to fall within a particular range of prices over 90 days) .
Catalent Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Catalent that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Catalent's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Catalent's value.| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2023-12-31 | 4 M | |
| Elliott Investment Management L.p. | 2023-12-31 | 4 M | |
| Amvescap Plc. | 2023-12-31 | 3.8 M | |
| Barclays Plc | 2023-12-31 | 3.7 M | |
| Capital Research & Mgmt Co - Division 3 | 2023-12-31 | 3 M | |
| Norges Bank | 2023-12-31 | 2.6 M | |
| Northern Trust Corp | 2023-12-31 | 2.1 M | |
| Goldman Sachs Group Inc | 2023-12-31 | 1.8 M | |
| Ameriprise Financial Inc | 2023-12-31 | 1.8 M | |
| Vanguard Group Inc | 2023-12-31 | 20.2 M | |
| Capital World Investors | 2023-12-31 | 19.1 M |
Catalent Historical Income Statement
Catalent Income Statement is one of the three primary financial statements used for reporting Catalent's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Catalent revenue and expense. Catalent Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Catalent's Total Operating Expenses is comparatively stable compared to the past year. Research Development is likely to gain to about 24 M in 2024, whereas Selling General Administrative is likely to drop slightly above 543.2 M in 2024. View More FundamentalsCatalent Stock Against Markets
Picking the right benchmark for Catalent stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Catalent stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Catalent is critical whether you are bullish or bearish towards Catalent at a given time. Please also check how Catalent's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Catalent without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
| All Next | Launch Module |
Catalent Corporate Directors
Catalent corporate directors refer to members of a Catalent board of directors. The board of directors generally takes responsibility for the Catalent's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Catalent's board members must vote for the resolution. The Catalent board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Bruce McEvoy | Director | Profile | |
| James Quella | Director | Profile | |
| Gregory Lucier | Independent Director | Profile | |
| Rolf Classon | Independent Director | Profile |
How to buy Catalent Stock?
Before investing in Catalent, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Catalent. To buy Catalent stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Catalent. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Catalent stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Catalent stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Catalent stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Catalent, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Catalent Stock please use our How to Invest in Catalent guide.
Already Invested in Catalent?
The danger of trading Catalent is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Catalent is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Catalent. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Catalent is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Catalent is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Catalent Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Catalent Stock. Highlighted below are key reports to facilitate an investment decision about Catalent Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalent. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Catalent Stock please use our How to Invest in Catalent guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Catalent Stock analysis
When running Catalent's price analysis, check to measure Catalent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalent is operating at the current time. Most of Catalent's value examination focuses on studying past and present price action to predict the probability of Catalent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalent's price. Additionally, you may evaluate how the addition of Catalent to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Catalent's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalent. If investors know Catalent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalent listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.15) | Earnings Share (7.18) | Revenue Per Share 22.579 | Quarterly Revenue Growth (0.11) | Return On Assets (0.01) |
The market value of Catalent is measured differently than its book value, which is the value of Catalent that is recorded on the company's balance sheet. Investors also form their own opinion of Catalent's value that differs from its market value or its book value, called intrinsic value, which is Catalent's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalent's market value can be influenced by many factors that don't directly affect Catalent's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalent's value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalent is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalent's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.